Friday, July 9, 2010

My Album of The Month(June)

File:Tristania-Ashes.jpg
Album: Ashes 
Year: 2005
Artist: Trstania

Ashes is the  4th full-length album of Tristania.
So impressive mix of soprano angelic and harsh death vocals by norwegian gothic metal band.
I highly enjoyed Ashes and i've been intermittently listening to it for about 3 years now.
I can  clearly remember the first hit came from "Cure"(4th Track) beautiful voice of Vibeke and wise poetic content of the song still haunts my memory and is undoubtedly one of the highlights of this album.
Then the "Shadowman" caught my eyes;once again Vibeke Sten's beauty-type vocals as the entering of the songs plays a dominant role.The song is all about restless mind struggling with the bizarre state of wakefullness.
Little by little as i listened to Ashes more carefully putting the mechanical aspect of Tristania music on my microscope;i found the whole album composed and mixed in a handy manner;no need to mention the professional production helped the sound keep its fresh and sharp resonance .
As i talked and praised Stene's pure beauty vocals; i think it's not fair to underrate Beast vocals of this album;
Tristania introduced Kjetil Ingebrethsen on harsh vocals;his performance is not far from excellent.
Lyrical themes are mainly focused on inner conflict and personally i find some parts rather hard to decipher.
Overall it is high quality 42 minutes of Gothic Metal with composure and solid structure meets the highest standard of the genre.


Pedram July 2010

Merck Closing Lab




Pharmaceutical giant Merck & Co., running counter to other drug makers’ moves to expand operations in the Boston area, yesterday said it will shut a five-year-old Cambridge research lab as part of a global cutback that will reduce the company’s worldwide payroll by 16,000 jobs, about 15 percent.
Merck would not specify how many jobs will be eliminated at its Kendall Square operation, which was developing cancer drugs. The lab had about 100 employees early last year, when it was run by its former owner, drug maker Schering-Plough Corp. An unspecified number of workers 
will move to another Merck lab in Boston’s Longwood Medical Area, which also does cancer-drug research, a Merck spokesman said.
The Cambridge site is the only US research center scheduled to be closed as part of Merck’s global consolidation, which also will include the shuttering of seven research-and-development sites across Europe and in Canada over the next two years.
Merck’s decision comes as other global pharmaceutical companies, most recentlySanofi-Aventis AG of France and Eli Lilly & Co. of Indianapolis, are boosting their presence in the Boston area to capitalize on its academic labs and biotech start-ups.
“We’ll still have a presence in Boston,’’ said Ron Rogers, a spokesman at Merck’s headquarters in Whitehouse Station, N.J. “It’s an important presence. This announcement doesn’t change that.’’
Rogers would not disclose how many people Merck employs at its Boston research lab, which is near Harvard Medical School and many of the city’s Harvard-affiliated teaching hospitals. The lab had about 250 employees in March 2009, the company said at that time.
Merck’s consolidation, which began in the fourth quarter of last year, follows its $41.1 billion acquisition of fellow New Jersey drug maker Schering-Plough, which opened the Cambridge lab at the beginning of 2006 and doubled it in size about six months later. Merck’s goal is to save $3.5 billion annually by 2012. Toward that end, the company already has eliminated about 11,000 jobs. Yesterday’s announcement covered additional research and manufacturing jobs.
“There will be some head count reduction from Cambridge, and some people will move over to our Boston facility,’’ Rogers said.
Even as Merck prepares to scale back local operations, Sanofi-Aventis is leasing space in Cambridge, where it plans to open a headquarters for its new cancer division. The $65 million expansion is expected to create 300 jobs.
Other drug makers with Boston research centers in the Boston area includeNovartis AG of Switzerland; Shire PLC, AstraZeneca PLC, and GlaxoSmithKlineof Britain; Takeda Pharmaceutical Co. and Dainippon Sumitomo Pharma Co. of Japan; and US pharmaceutical colossus Pfizer Inc. of New York. Last week, Lilly said it was grabbing a foothold in the area by purchasing Alnara Pharmaceuticals Inc.
Merck KGaA, a German drug and chemicals company unrelated to Merck & Co., in March said it plans to move the headquarters of its US chemicals business to Billerica after its acquisition of life sciences toolmaker Millipore Corp. With that buyout, Germany’s Merck will have 1,676 employees in Massachusetts and New Hampshire.


@Bostonglobe.com

Sunday, July 4, 2010

Benign Paroxysmal Positional Vertigo


Benign paroxysmal positional vertigo is a common peripheral vestibular disorder. It is caused by loose otoconia, which detach from the utricular macula and fall into any one of the three semicircular canals. Patients report brief episodes of rotary vertigo triggered by changes in head position. The most common form of the disorder affects the posterior semicircular canal and is diagnosed with the Dix–Hallpike maneuver. A positive Dix–Hallpike test is manifested as upbeating torsional nystagmus with a fast component that rotates toward the undermost ear. This nystagmus may be seen with the unaided eye but is often more pronounced if fixation is eliminated with the use of Frenzel lenses or video-oculography goggles. Treatment of benign paroxysmal positional vertigo is directed at returning the displaced otoconia to their proper location in the inner ear. Various effective particle-repositioning maneuvers have been developed and are curative in most cases.

video:positive Dix-Hallpike test

@NEJM

Wednesday, June 30, 2010

اردوغان: اسرائيل همچنان دوست ماست


۰۹ تير ۱۳۸۹
نخست‌وزير تركيه اذعان كرد كه "تل‌آويو " همچنان دوست "آنكارا " است.

به گزارش فارس به نقل از روزنامه سعودي "الرياض "، "رجب طيب اردوغان " نخست‌وزير تركيه تاكيد كرد كه "تل‌آويو " همچنان دوست "آنكارا " است و تركيه تنها با دولت كنوني نتانياهو " نخست‌وزير اسرائيل مشكل دارد.
وي با تاكيد بر اينكه دولت نتانياهو بزرگترين مانع در مقابل صلح خاورميانه است، از آمريكا خواست تا نقش خود را در قبال پيامدهاي حمله اسرائيل به كاروان كشتي‌هاي كمك‌رسان به غزه ايفا كند.
وي در مصاحبه با شبكه تلويزيوني آمريكايي "پي‌بي‌اس " گفت: تركيه همچنان دوست اسرائيل است اما دولت كنوني اسرائيل به نخست‌وزيري بنيامين نتانياهو بزرگترين مانع فراروي تحقق صلح در خاورميانه است.
وي اين چهار شرط را عذرخواهي اسرائيل از تركيه به دليل حمله به كاروان آزادي غزه و كشتار فعالان صلح، پرداخت غرامت به كشته شدگان در اين حمله، پذيرش درخواست بان كي مون دبيركل سازمان ملل براي تشكيل كميته تحقيق بين المللي درباره اين حمله و لغو كامل محاصره غزه عنوان كرد.
اردوغان بار ديگر تاكيد كرد كه تركيه به غرب پشت نكرده و ضديتي با غرب يا اسرائيل ندارد.
اردوغان در ادامه تصريح كرد: دولت آمريكا بايد بدليل وجود دو آمريكايي در ميان كشتگان كاروان ‌آزادي، رهبري و مديريت اوضاع را برعهده بگيرد.
وي در ادامه به "فرقان دوغان " (19 ساله) كه داراي دو تابعيت تركي و آمريكايي بود و در تجاوز رژيم صهيونيستي به كاروان آزادي نيز حضور داشت، اشاره كرد.
نخست‌وزير تركيه در ادامه افزود: بايد به جنبش حماس فرصت اداره دولت داده شود زيرا اين جنبش در انتخابات فلسطين پيروز شده بود.
اردوغان ديروز نيز در گفت‌وگو با روزنامه استار تركيه در رابطه با روابط متشنج آنكارا و تل‌آويو چهار شرط را براي از بين رفتن تنش در روابط طرفين عنوان كرد.


© 2010 - الف

On Their Early Exit


TEHRAN - The elimination of England, France and the United States in the early stages of the World Cup was a just reward for their ill-treatment of Iran, its foreign minister said on Tuesday.
Iran did not qualify for the tournament in South Africa but fans have been glued to their televisions nonetheless in a country where football is the number one sport.
While the United States - often referred to by Iran's leaders as "the great Satan" - were never a favourite at the tournament, the elimination of England and France before the quarter-finals was a crushing blow to their fans back home.
England and the U.S. both lost in second round matches while France and world champions Italy fell in the opening group stage.
Foreign Minister Manouchehr Mottaki said they had all got what they deserved after they backed a new round of sanctions against Iran over its nuclear programme which the West fears may be aimed at making a bomb, something Tehran denies.
"Whatever we witness today in the international political arena has been identically manifested in the 19th tournament of the World Cup," Mottaki was quoted as saying by Iran's official news agency IRNA.
"Those countries which played a key role in imposing new sanctions against Iran - like England, America and France - were all eliminated in the preliminary phases," he said.
Brazil, which voted against the sanctions, is one of the favourites to win having impressively reached the last eight with a crushing 3-0 victory over Chile on Monday.
Iran played at the last World Cup finals in Germany four years ago but finished bottom of their qualifying group.
In 1998, they famously beat the United States 2-1 although neither side went through to the next round.

@Reuters

Sunday, June 27, 2010

Light Grenades

I was listening to Incubus today and i became curious about this alternative rock band;so i decided to search about it ,read some reviews and give it a second try.
I found Brandon Boyd explanation about Light Grenade's theme;just to remind me how meaningful and pithy a sub-culture can be ;
This is Incubus weaving words with melodies !


"There's a song called that on the record and it felt like the most pertinent conceptual aspect of the album, the idea of throwing ideas at problems and the ideas explode with light and good results and intention on consciousness. So I started imagining imagery of students in different countries protesting and throwing Molotov cocktails with masks over their faces. But there's one brave student who runs up to the police line and, as opposed to throwing rocks or things that destroy, there's this concept of that one courageous, lonely student running up and throwing ideas and having them actually change things. It just seemed kind of a cool concept: the redefining of weaponry."
Brandon Boyd(from wiki)

Friday, June 25, 2010

Capital Of Longevity










Last winter, the New York City Department of Health released figures that told a surprising story: New Yorkers are living longer than ever, and longer than most people in the country. A New Yorker born in 2004 can now expect to live 78.6 years, nine months longer than the average American will. What’s more, our life expectancy is increasing at a rate faster than that of most of the rest of the country. Since 1990, the average American has added only about two and a half years to his life, while we in New York have added 6.2 years to ours. In the year 2004 alone, our life expectancy shot up by five months—a stunning leap, because American life spans normally increase by only a month or two each year. When these figures came out, urban-health experts were impressed and slightly dazed. It turns out the conventional wisdom is wrong: The city, it seems, won’t kill you. Quite the opposite. Not only are we the safest big city in America, but we are, by this measure at least, the healthiest.

The “average life expectancy” of a city is a statistically curious number. It’s not really a prediction about how long you’re going to live. It’s an average of how long everyone here lives—and thus it forms a good barometer of the overall health of the city. In particular, a city’s average life span is sensitive to the rates at which people die too young. Since the average New York life expectancy is now 78.6 years, anytime someone dies younger than that, it drags the city’s overall average down slightly.
The math works like this. Imagine that one man dies of AIDS at age 25. Since he was statistically supposed to live to 78.6 years, he’s died about 50 years too early, so he shaves 50 years off the city’s overall pool of life. If one Wall Street guy collapses of a heart attack at age 65, he shaves only ten years off. You’d have to have five Wall Streeters die at that age to equal the impact of one AIDS victim. By the same logic, one infant’s dying during childbirth—77.8 years too early—is equal to ten people’s succumbing to lung cancer at age 70. It is a very weird form of horse trading. The more you’re able to prevent young people—folks in their twenties and thirties—from dying, the more rapidly you boost a city’s overall life expectancy.
And this is precisely what the city has done, through a combination of smart public policy and sheer luck. All the boons of the nineties—the aggressive policing, the dramatic drop in crime, the renaissance of the city’s parks and street life, the freakish infusion of boom-time wealth—played a part. Take the miraculous evaporation of the homicide rate. In 1990, a stunning 2,272 New Yorkers were murdered; in 2005, that number dropped to 579. Since a majority of those being killed were younger men, the reduced murder rate alone added tens of thousands of years to New York’s life-expectancy pool. Another big drop was in HIV mortality rates. In 1994, deaths from AIDS peaked at over 7,100, but the arrival of better drugs and health care began to whittle that number by 80 percent—so in 2005, only 1,419 died of AIDS. Again, the majority of the lives saved here were those of younger men, resulting in a disproportionately big upward leap in our city’s life span. In 1989, the infant-mortality rate was 13.3 babies per 1,000, and by 2004, it had been halved, to 6.1, both because medical treatment improved and because alcohol and drug addictions eased. To top it off, drug-related deaths, another arena with disproportionately younger victims, tapered off, too.
Homicide, AIDS, and drugs are characteristically New York ways to die young, of course, so it’s no surprise that when we sharply decreased the fatalities they caused, we caught up with the rest of the country. But here’s the thing: It’s not just that we’ve conquered these urban blights. Cancer and cardiac arrest are down, too. The number of people in the city dying from heart disease has dropped by a third in the last twenty years, and cancer rates have slid by nearly a fifth. And again in these cases, New York is getting healthier faster than the rest of the U.S.
In essence, there is a health gap emerging between our massive metropolis and the rest of the country—some X factor that’s improving our health in subtle, everyday ways. In fact, a back-of-the-envelope calculation shows that once you take out those uniquely New York ways to die—AIDS, homicide, etc.—we’ve still added at least 200,000 extra years onto the city’s life-expectancy tables since 1980, making crucial advances in the same health areas the rest of the country struggles with. Like many New Yorkers, I’d moved here with some trepidation—always figuring that the stress, pollution, and 60-hour workweeks would knock about five years off my life. I was wrong—precisely wrong. But where, exactly, is our excess life coming from? 



Clive Thompson
@ nymag.com

Thursday, June 17, 2010